03-Jun-2022 | Facts and Factors
According to Facts and Factors, the Global Breast Biopsy Market was valued at USD 702.13 million in 2021 and is predicted to increase at a CAGR of 7.3% to USD 1,109.35 million by 2028. The study examines the market in terms of revenue in each of the major regions, which are classified into countries.
Breast biopsy market expansion is fuelled by the growing sensitivity of women to mammary cancer in all nations, as well as awareness initiatives and screenings conducted in their favor. The biopsy market has grown as a result of a broad and vigorous research environment, which has contributed to the development of more accurate and minimally invasive treatments for the early detection of breast cancer. Governments have also made efforts to foster a stable and comprehensive environment for cancer research, which has aided in the development of these diagnostic tools.
Browse the full “Breast Biopsy Market By Product (Biopsy Needles, Guidance Systems, Biopsy Tables, Localization Wires, Assay Kits, Liquid Biopsy Instruments, Others), By Type (Needle Breast Biopsy, Core Needle Biopsy (CNB), Fine Needle Aspiration Biopsy (FNAB), Vacuum-assisted Biopsy (VAB), Open Surgical Breast Biopsy, Excisional, Incisional, Liquid Breast Biopsy, Circulating Tumor Cells, Circulating Tumor DNA (CtDNA), Other Biomarkers), By Guidance (Image-Guided Biopsy, Mammography-guided Stereotactic Biopsy, Ultrasound-guided Biopsy, MRI-guided Biopsy, Other Guidance Techniques, Liquid Biopsy, NGS-based Biopsy, PCR-based Biopsy, Microarray-based Biopsy), By Application (Early Cancer Screening, Therapy Selection, Treatment Monitoring, Recurrence Monitoring), and By Region - Global Industry Insights, Growth, Size, Share, Comparative Analysis, Trends and Forecast 2022 – 2028" report at https://www.fnfresearch.com/breast-biopsy-market
Additionally, favorable reimbursements have substantially improved the health of this sector. The significant market expansion throughout the study period can be due to new product approvals and launches, as well as a growing desire for less invasive and graphics-based needle biopsies (such as vacuum-assisted biopsy and core needle biopsy). The occurrence of side effects and infections following biopsy stymies the growth of these diagnostic tools.
In terms of Product, the biopsy needles segment is likely to hold a significant share of the breast biopsy market because of the increasing acceptance of image-guided techniques in both developed and developing nations, as well as the introduction of technologically advanced and unique designs. For example, consider the tri-axial needle, which is made up of a pincer needle on the outside, an outer cutting needle, and a sharp stylet on the inside. Due to the needle design, healthcare providers can cut through tissue without squeezing it. Even with its unique form, the needle is easily visible under ultrasonography and CT, which are often used for biopsy guiding.
In terms of Guidance, the liquid biopsy category is expected to expand the most during the projection period. Liquid biopsy has emerged as a game-changing method that is expanding the scope of oncology diagnoses. The considerable rise of the segment can be attributable to the increasing usage of innovative NGS-based assays and droplet digital PCR technology in most developed countries for performing liquid biopsies. Companies in the industry are investing more in research and development in order to bring new items to market. As a result, continuing clinical trials and a potential product pipeline will push market growth even further.
The breast biopsy market in the Asia Pacific is expected to develop the fastest. The healthcare infrastructure in growing economies such as China, India, and South Korea is rapidly evolving, prompting hospitals and breast care centers to make significant expenditures on modern systems (such as liquid breast biopsy and vacuum-assisted biopsy devices, among others). This reason is propelling the Asia Pacific breast biopsy market forward. Furthermore, rising breast cancer prevalence, an increase in the number of breast cancer awareness initiatives, and increased government investment in breast cancer research studies are the primary drivers driving the growth of the Asia Pacific breast biopsy market.
Report Scope
Report Attribute |
Details |
Market Size in 2021 |
USD 702.13 Million |
Projected Market Size in 2028 |
USD 1,109.35 Million |
CAGR Growth Rate |
7.3% CAGR |
Base Year |
2021 |
Forecast Years |
2022-2028 |
Key Market Players |
Hologic, Inc. (US), Becton, Dickinson and Company (US), Danaher Corporation (US), Merit Medical Systems (US), Medtronic (Ireland), IZI Medical Products (US), Argon Medical (US), STERYLAB S.r.l. (Italy), Scion Medical Technologies, LLC (China), QIAGEN (Netherlands), Biocept Inc. (US), Bio-Rad Laboratories, Inc. (US), F. Hoffmann-La Roche Ltd (Switzerland), Menarini Silicon Biosystems, Spa (Italy), Exact Sciences Corporation (US), Thermo Fisher Scientific, Inc. (US), Cardiff Oncology, Inc. (US), Myriad Genetics, Inc. (US), Illumina, Inc. (US), Fluxion Biosciences Inc (US), and Others |
Key Segment |
By Product, Type, Guidance, Application, and Region |
Major Regions Covered |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
Purchase Options |
Request customized purchase options to meet your research needs. Explore purchase options |
Some of the major companies operating in the global breast biopsy market are Hologic, Inc. (US), Becton, Dickinson and Company (US), Danaher Corporation (US), Merit Medical Systems (US), Medtronic (Ireland), IZI Medical Products (US), Argon Medical (US), STERYLAB S.r.l. (Italy), Scion Medical Technologies, LLC (China), QIAGEN (Netherlands), Biocept Inc. (US), Bio-Rad Laboratories, Inc. (US), F. Hoffmann-La Roche Ltd (Switzerland), Menarini Silicon Biosystems, Spa (Italy), Exact Sciences Corporation (US), Thermo Fisher Scientific, Inc. (US), Cardiff Oncology, Inc. (US), Myriad Genetics, Inc. (US), Illumina, Inc. (US), Fluxion Biosciences Inc (US) and among others.
The global breast biopsy market is segmented as follows:
By Product
- Biopsy Needles
- Guidance Systems
- Biopsy Tables
- Localization Wires
- Assay Kits
- Liquid Biopsy Instruments
- Others
By Type
- Needle Breast Biopsy
- Core Needle Biopsy (CNB)
- Fine Needle Aspiration Biopsy (FNAB)
- Vacuum-assisted Biopsy (VAB)
- Open Surgical Breast Biopsy
- Excisional
- Incisional
- Liquid Breast Biopsy
- Circulating Tumor Cells
- Circulating Tumor DNA (CtDNA)
- Other Biomarkers
By Guidance
- Image-Guided Biopsy
- Mammography-guided Stereotactic Biopsy
- Ultrasound-guided Biopsy
- MRI-guided Biopsy
- Other Guidance Techniques
- Liquid Biopsy
- NGS-based Biopsy
- PCR-based Biopsy
- Microarray-based Biopsy
By Application
- Early Cancer Screening
- Therapy Selection
- Treatment Monitoring
- Recurrence Monitoring
By Region
- North America
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Nordic Countries
- Benelux Union
- Belgium
- The Netherlands
- Luxembourg
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Southeast Asia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Rest of Southeast Asia
- Rest of Asia Pacific
- The Middle East & Africa
- Saudi Arabia
- UAE
- Egypt
- South Africa
- Rest of the Middle East & Africa
- Latin America
- Brazil
- Argentina
- Rest of Latin America
About Us:
Facts & Factors is a leading market research organization offering industry expertise and scrupulous consulting services to clients for their business development. The reports and services offered by Facts and Factors are used by prestigious academic institutions, start-ups, and companies globally to measure and understand the changing international and regional business backgrounds. Our client’s/customer’s conviction on our solutions and services has pushed us in delivering always the best. Our advanced research solutions have helped them in appropriate decision-making and guidance for strategies to expand their business.
Contact Us:
Facts & Factors
A 2108, Sargam,
Nanded City,
Sinhagad Road,
Pune 411041, India
USA: +1-347-989-3985
Email: [email protected]
Web: https://www.fnfresearch.com
